1. ABDELRAHIM, Hisham Mohammed, et al.

Addition of Insulin to Treatment Regimen in

Type 2 Diabetes: The Significance of Age and Duration among Sudanese Diabetic
Patients. Pharmacology & Pharmacy, 2019, 10.10: 456.
2. WORLD HEALTH ORGANIZATION, et al. Classification of diabetes mellitus. 2019.
3. SAEEDI, Pouya, et al. Global and regional diabetes prevalence estimates for 2019 and
projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes
Atlas. Diabetes research and clinical practice, 2019, 157: 107843.
4. ALFAIFI, Mohammed. Contribution of genetic variant identified in HHEX gene in the
Overweight Saudi patients confirmed with Type 2 Diabetes Mellitus. Saudi Journal of
Biological Sciences, 2022, 29.2: 804-808.
5. ALKHARSAH, Khaled R., et al. Low levels of soluble DPP4 among Saudis may have
constituted a risk factor for MERS endemicity. Plos one, 2022, 17.4: e0266603.
6. WILSON, M.J., et al. Dipeptidylpeptidase IV activities are elevated in prostate cancers and
adjacent benign hyperplastic glands. Journal of andrology, 2000; 21(2): 220-226.
7. GONG, Quan; RAJAGOPALAN, Sanjay; ZHONG, Jixin. Dpp4 inhibition as a therapeutic
strategy in cardiometabolic disease: Incretin-dependent and-independent
function. International Journal of Cardiology, 2015, 197: 170-179.
8. KLEMANN, Christian, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's
(DPP4) entanglement in the immune system. Clinical & Experimental Immunology, 2016,
185.1: 1-21.
9. LAMBEIR, Anne-Marie, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on
structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical reviews
in clinical laboratory sciences, 2003, 40.3: 209-294.
10. DEACON, Carolyn F. Physiology and pharmacology of DPP-4 in glucose homeostasis and
the treatment of type 2 diabetes. Frontiers in endocrinology, 2019, 10: 80.
11. RÖHRBORN, Diana; WRONKOWITZ, Nina; ECKEL, Juergen. DPP4 in diabetes. Frontiers
in immunology, 2015, 6: 386.
12. BAKHTADZE, Ekaterine. Exploring the Grey Zone between Type 1 and Type 2 Diabetes.
Lund University, 2009.
13. BARREIRO, Luis B., et al. Natural selection has driven population differentiation in modern
humans. Nature genetics, 2008, 40.3: 340-345.
14. Sauvé M, Ban K, Momen MA, et al.. Genetic deletion or pharmacological inhibition of
dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in
mice. Diabetes 2010;59:1063–73. 
15. PAREDES, Sílvia, et al. Novel and traditional lipid profiles in Metabolic Syndrome reveal a
high atherogenicity. Scientific reports, 2019, 9.1: 1-7.
16. Radwan Hamoud, Ali Ahmed. Association of genetic polymorphisms of dipeptidyl peptidase-
4 with Type 2 Diabetes Mellitus in Malaysian subjects/Radwan Hamoud Ali Ahmed. Diss.
University of Malaya, 2017.
17. XING, Xiaomin, et al. Association between DPP4 gene polymorphism and serum lipid levels
in Chinese type 2 diabetes individuals. Neuropeptides, 2016, 60: 1-6.
18. AGHILI, Nima, et al. Polymorphisms in dipeptidyl peptidase IV gene are associated with the
risk of myocardial infarction in patients with atherosclerosis. Neuropeptides, 2012, 46.6: 367-
371.
19. BAILEY, Swneke D., et al. Variation at the DPP4 locus influences apolipoprotein B levels in
South Asians and exhibits heterogeneity in Europeans related to BMI. Diabetologia, 2014,
57.4: 738-745.
20. Song Y, Yang Y, Zhang J, et al. The apoB100/apoAI ratio isindependently associated with
the severity of coronary heart disease: a cross sectional study in patients undergoing coronary
angiography. Lipids Health Dis 2015;14:150.
21. BOUCHARD, Luigi, et al. ZFP36: a promising candidate gene for obesity-related metabolic
complications identified by converging genomics. Obesity surgery, 2007, 17.3: 372-382.